ArticleIJID regions2026
Surveillance of circulating SARS-CoV-2 variants in the Republic of Serbia during 2024.
Article in IJID regions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The COVID-19 epidemic, caused by SARS-CoV-2, has spread worldwide and remains a major public health challenge. The objective of this study was to assess the prevalence of COVID-19 and characterize the circulating SARS-CoV-2 lineages in the Republic of Serbia during 2024. Methods: We analyzed SARS-CoV-2-positive samples collected throughout 2024 in Serbia. Viral lineages were identified based on sequencing of the gene encoding the spike protein. The distribution of detected lineages was compared with available European data to evaluate regional differences in variant circulation. Results: The distribution of SARS-CoV-2 lineages in Serbia differed substantially from the European average. The most prevalent variant detected in Serbia was JN.1.16, whereas KP.3.1.1 predominated in Europe. In addition, 95% of analyzed viral sequences contained the ins_S:16:MPLF insertion, a characteristic feature of the GRA clade. Conclusion: These findings demonstrate that the distribution of SARS-CoV-2 lineages in Serbia in 2024 differed from the average European distribution in 2024. The observed differences should be considered when evaluating the need for booster vaccination and optimizing national vaccination strategies. To our knowledge, this study provides the only available data on SARS-CoV-2 lineage circulation in Serbia for 2024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.